Small-molecule-based inhibition of the E3 activity of UBE3A would perturb not only E6-dependent ubiquitination of p53 but also other physiological substrates, which may elicit a concern about adverse effects when UBE3A enzymatic inhibitors are used to treat HPV-associated cancers. Here, TP53 is linked to cancer.